Notably, patients with BRAF-mutated MSI-H CRC had favorable outcomes with BRAF-targeted inhibitors in the phase III BEACON CRC trial [220], suggesting that molecular targeted therapy holds promise for MSI-H/dMMR GC. This evidence concerns the gene BRAF and colorectal carcinoma.